Name: Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2 (en Inglés)
Price: 98.04 PEN
Availability: InStock
Author: The Law Library
ISBN: 9781727540314

portada Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2 (en Inglés)

Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2 (en Inglés)

Formato

Libro Físico

Autor

The Law Library

Editorial

Createspace

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

25.4 x 17.8 x 0.3 cm

Peso

0.12 kg.

ISBN13

9781727540314

Categorías

Teoría general del derecho

Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2 (en Inglés)

The Law Library (Autor) · Createspace · Tapa Blanda

Libro Nuevo Importado

Envío: 17 a 22 días háb.

S/ 217,86S/ 98,04

-55%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

S/ 98,04

Llega entre el 13 Ago y el 21 Ago a CERCADO DE LIMA, Lima. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2 (en Inglés)"

Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2018 Edition) The Law Library presents the complete text of the Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2018 Edition). Updated as of May 29, 2018 The Food and Drug Administration (FDA or the Agency) is amending its regulations to implement certain drug shortages provisions of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA). The rule requires all applicants of covered approved drugs or biological products-including certain applicants of blood or blood components for transfusion and all manufacturers of covered drugs marketed without an approved application-to notify FDA electronically of a permanent discontinuance or an interruption in manufacturing of the product that is likely to lead to a meaningful disruption in supply (or a significant disruption in supply for blood or blood components) of the product in the United States. This book contains: - The complete text of the Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products (US Food and Drug Administration Regulation) (FDA) (2018 Edition) - A table of contents with the page number of each section